Heterogeneity in Malignant Pleural Mesothelioma.
- Oehl K Department of Thoracic Surgery, University Hospital Zurich, 8091 Zürich, Switzerland. Kathrin.Oehl@usz.ch.
- Vrugt B Institute of Pathology and Molecular Pathology, University Hospital Zürich, 8091 Zürich, Switzerland. Bart.Vrugt@usz.ch.
- Opitz I Department of Thoracic Surgery, University Hospital Zurich, 8091 Zürich, Switzerland. Isabelle.Schmitt-Opitz@usz.ch.
- Meerang M Department of Thoracic Surgery, University Hospital Zurich, 8091 Zürich, Switzerland. mayura.meerang@usz.ch.
- 2018-06-01
Published in:
- International journal of molecular sciences. - 2018
cancer stem cells
chemoresistance
inter-tumor heterogeneity
mesothelioma
spatial intra-tumor heterogeneity
targeted therapy
temporal intra-tumor heterogeneity
Antineoplastic Agents
Genetic Heterogeneity
Humans
Lung Neoplasms
Mesothelioma
Neoplastic Stem Cells
English
Despite advances in malignant pleural mesothelioma therapy, life expectancy of affected patients remains short. The limited efficiency of treatment options is mainly caused by inter- and intra-tumor heterogeneity of mesotheliomas. This diversity can be observed at the morphological and molecular levels. Molecular analyses reveal a high heterogeneity (i) between patients; (ii) within different areas of a given tumor in terms of different clonal compositions; and (iii) during treatment over time. The aim of the present review is to highlight this diversity and its therapeutic implications.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.3390/ijms19061603
- PMID 29848954
- Persistent URL
- https://sonar.ch/global/documents/259901
Statistics
Document views: 28
File downloads:
- Full-text: 0